SCHEDULE: Deerfield Funds Boost Stake in Larimar Therapeutics to 35.81% Following $30 Million Offering

Deerfield Management and its affiliated funds have increased their beneficial ownership in Larimar Therapeutics, Inc. to 35.81% of common stock after acquiring an additional 9.37 million shares for $30 million in a recent underwritten offering.

Summary

• Deerfield Management Company, L.P. and its affiliated funds (Deerfield Private Design Fund III, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Private Design Fund IV, L.P., and Deerfield Partners, L.P.) collectively reported beneficial ownership of 30,667,474 shares of Larimar Therapeutics, Inc. common stock.
• This represents 35.81% of the outstanding common stock, based on 85,590,392 shares outstanding after the July 2025 Offering.
• On July 31, 2025, Deerfield Private Design Fund III, Deerfield Private Design Fund IV, and Deerfield Healthcare Innovations Fund purchased a total of 9,374,000 shares in an underwritten offering conducted by Larimar Therapeutics.
• The shares were acquired at a price of $3.20 per share, totaling an aggregate purchase price of $30,000,000.00.
• The individual purchases were: Deerfield Private Design Fund III (3,387,529 shares for $10,840,092.80), Deerfield Private Design Fund IV (3,387,539 shares for $10,840,124.80), and Deerfield Healthcare Innovations Fund (2,599,932 shares for $8,319,782.40).
• The funds utilized available cash assets to acquire these shares.
• The beneficial ownership also includes 60,500 shares issuable upon exercise of fully vested options held by Jonathan Leff, an employee of Deerfield Management Company, L.P., for the benefit and direction of Deerfield Management Company, L.P.

Sentiment

Score: 8

Explanation: The significant increase in beneficial ownership by a major healthcare-focused investment firm like Deerfield Management, through a direct capital raise by the company, indicates strong investor confidence and provides fresh capital to the issuer. This is generally a positive signal for the company's prospects.

Positives

• A significant increase in beneficial ownership by a major institutional investor, Deerfield Management, signals strong confidence in Larimar Therapeutics.
• The acquisition of shares through an underwritten offering indicates a direct investment into the company's capital structure, providing the company with fresh capital.
• The investment was made using available cash assets, suggesting financial liquidity from the investor's side.

Future Outlook

The filing states the shares were acquired for "investment purposes," which is a general forward-looking statement indicating an intent to hold or manage the investment for future returns. No specific guidance or projections are provided.

Industry Context

This filing indicates continued investment interest from a specialized healthcare fund (Deerfield) in a biotechnology company (Larimar Therapeutics). Such investments are common in the biotech sector, where companies often rely on capital raises to fund research, development, and clinical trials. Deerfield's increased stake suggests a positive view on Larimar's potential within the healthcare industry.

Comparison to Industry Standards

• Deerfield Management is a prominent healthcare-focused investment firm. Their substantial and increasing stake in Larimar Therapeutics aligns with typical strategies of specialized funds taking significant positions in promising biotech companies.
• A 35.81% beneficial ownership stake is a very substantial position for an institutional investor, often indicating a strategic interest beyond a passive investment, potentially leading to board representation or significant influence, which is common for large healthcare-focused funds in smaller biotech firms.
• The acquisition through an underwritten offering at a specific price ($3.20 per share) is a standard method for companies to raise capital and for institutional investors to acquire large blocks of shares.

Stakeholder Impact

• Shareholders: Existing shareholders experienced dilution due to the underwritten offering, but the significant investment by Deerfield Management could be seen as a vote of confidence, potentially stabilizing or increasing share price in the long term.
• Company (Larimar Therapeutics): Received $30 million in new capital, which can be used to fund operations, research, and development, potentially accelerating its strategic objectives.

Next Steps

• The acquired shares are for "investment purposes," implying ongoing monitoring and potential future actions related to the investment.

Key Dates

Recommendation

The filing indicates a significant vote of confidence from a major institutional investor, Deerfield Management, which has substantially increased its stake in Larimar Therapeutics through a direct capital raise. This influx of capital and strong institutional backing are positive signals. However, as a Schedule 13D, it primarily reports ownership changes and does not provide operational or financial performance updates from the company itself. Therefore, while the institutional interest is a positive indicator, a "hold" recommendation is appropriate until further operational or clinical updates from Larimar Therapeutics provide a more complete picture of its fundamental performance and future prospects. The capital raise also implies dilution, which needs to be weighed against the positive signal of the investment.

Keywords

Larimar Therapeutics, Deerfield Management, Schedule 13D, beneficial ownership, common stock, underwritten offering, institutional investment, healthcare, biotechnology, equity